Navigation Links
Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
Date:6/8/2012

SOUTH PLAINFIELD, N.J., June 8, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. today announced the results from a Phase 3 study of ataluren, an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). The results demonstrated positive trends in lung function as measured by FEV1 (forced expiratory volume in one second) and in the secondary outcome measure, rate of pulmonary exacerbations. Results also showed a substantial ataluren treatment effect in FEV1 and exacerbation rate in the pre-specified subpopulation of patients not receiving chronic inhaled antibiotics, representing approximately one half of the study population. These data were presented at the European Cystic Fibrosis Society Conference in Dublin, Ireland.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO )

"The data from this trial are promising. Ataluren has the potential to provide benefit to patients with nonsense mutation cystic fibrosis, who currently have few treatment options. Nonsense mutations do not produce any functional CFTR protein and therefore generally result in a more severe form of cystic fibrosis," stated Michael Konstan, M.D., a principal investigator at University Hospitals Rainbow Babies and Children's Hospital in Cleveland, Ohio. "Correcting a nonsense mutation in the cystic fibrosis transmembrane conductance regulator gene is a big challenge. Over 48 weeks, the decrease in FEV1 in ataluren was 50% less than the decrease on placebo, which is a substantial difference. It is also very important to note that the FEV1 and exacerbations tracked closely." 

This Phase 3 study, which was conducted across 11 countries, was a double-blind, placebo-controlled study comparing ataluren (n=116) to placebo (n=116) in nmCF patients. The primary endpoint, the relative change from baseline in %-predicted FEV1 at 48 weeks, showed a positive trend favoring atalur
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
2. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
3. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
4. Sorrento Therapeutics Awarded Third Phase I STTR Grant
5. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
6. Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
7. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
8. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
9. Preliminary Phase 2 Data of Ocera Therapeutics OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
10. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
11. Clinilabs Opens Phase I Unit In Eatontown, New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 According to Kalorama ... needed to make Big Data in healthcare a reality, ... As part of the American Recovery and Reinvestment Act, ... record (EMR) projects and penalties will start applying soon ... Information, in its complete study of the EMR industry, ...
(Date:8/19/2014)...  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management ... and Regeneron will host an IR Thematic Conference Call on Alirocumab ... 2014 , Baird 2014 Healthcare Conference at 4:05 ... , Citi,s 9 th Annual Biotech Conference at ... , Morgan Stanley Global Healthcare Conference at 8:45 ...
(Date:8/19/2014)... and MENLO PARK, Calif. , ... DMPI) ("DelMar" "the company") announced today a protocol amendment to ... been filed with the U.S. Food and Drug Administration (FDA) ... has been opened at three clinical trial sites in ... confirmed that gross proceeds of US$2.9 million have been raised ...
Breaking Medicine Technology:Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7
... Oct. 6 Complete,Genomics Inc., a newly launched, ... Systems Biology (ISB) today announced their,partnership to conduct ... of the project, Complete Genomics will use its ... samples provided by,ISB. Then, once proof-of-concept has been ...
... will host a conference call today, Monday, October ... to review the outcome of the interim analysis ... known as D9902B),clinical trial of PROVENGE(R) (sipuleucel-T), the ... advanced prostate,cancer., Those interested may ...
Cached Medicine Technology:Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study 2Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2
(Date:8/20/2014)... (PRWEB) August 20, 2014 This ... line of software defined networking, high availability cloud ... portfolio of Resellers, while allowing OPEN-V to sell ... is pleased to work with OPEN-V on this ... Donald Hows, manager distribution channels at storageFOUNDRY. "Nautilus ...
(Date:8/19/2014)... BambooIndustry.com, a well-known bamboo product manufacturer and retailer, ... recently. The company is excited to reveal the new items, ... for all clients. Now, every customer can get a discounted ... until August 30. , The company’s deckings are made ... for supreme durability. They are perfect for a dining room, ...
(Date:8/19/2014)... Crosley Law Firm, PC has reached a confidential ... Star Bakery for an undisclosed amount. The two claimants, Pete ... of 2011, respectively. The injuries were caused by two different ... to the left hand of each man. , At the ... short-staffed, having lost 200 of its, 500 workers in connection ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 Recently, Skmen.com, an ... assortment of 2014 bohemian dresses . In addition to ... these elegant items. Now, all of them are available at ... puts emphasis on product design and quality. Its beautiful bohemian ... purple, blue and many others. Owing to its top quality ...
(Date:8/19/2014)... involved in multitasking and ways to train it have ... Institut universitaire de griatrie de Montral and the University ... predict the effectiveness of this training. Cooking while having ... or driving while listening to a radio show ... lives. Unfortunately, it decreases with age, which makes it ...
Breaking Medicine News(10 mins):Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3Health News:Promotional Bamboo Deckings from Well-known Online Supplier BambooIndustry.com 2Health News:Crosley Law Firm Reaches Settlement for Hand Amputation Victims at Commercial Bakery 2Health News:2014 Bohemian Dresses Now for Sale at Skmen.com 2Health News:Targeted brain training may help you multitask better 2
... NEW YORK, Aug. 11 Healthcare reform has become a hot button ... one organization,s attempts to clear the air and separate fact from fiction. ... http://inr.mediaseed.tv/oneClip_C/?feed=_QhsLVZADdDFnJstv e QtY97yVQFUg6so , ... and photos for free and unrestricted use at http://www.medi ...
... counters effects of hormone therapy, study finds , TUESDAY, ... has worked well in a trial of men whose ... taking for prostate cancer, researchers report. , The drug, ... hopes to market for fracture prevention, not only in ...
... PHILADELPHIA A new study conducted at the ... in Philadelphia, Pennsylvania shows an investigational, orally-inhaled therapy ... phase three FREEDOM-301 trial for the orally-inhaled migraine ... from symptoms such as pain, nausea and light ...
... team approach to preventive healthcare delivery for older adults ... Institute improves health and quality of life, decreased emergency ... second year the new model saved money for the ... in the third year, a year after the home-based ...
... , , , ... 11 Masimo (Nasdaq: MASI ), the ... pulse oximetry, and Oridion (SIX Swiss Exchange: ORIDN), a ... an agreement to establish compatibility and connectivity between Oridion ...
... Fla., Aug. 11 Jeff Korte, former Major with the Florida Division ... Investigative Unit (SIU) for Litigation Solutions, LLC. , ... enforcement experience to Litigation Solutions, spending the past 20 years with the ... in 2008. , , During his tenure ...
Cached Medicine News:Health News:New Bone-Building Drug Promising Against Prostate Cancer 2Health News:New Bone-Building Drug Promising Against Prostate Cancer 3Health News:Aging with GRACE: New health care delivery model improves outcomes, saves money 2Health News:Aging with GRACE: New health care delivery model improves outcomes, saves money 3Health News:Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream(TM)20 Portable Bedside Monitors into the Masimo Patient SafetyNet(TM) System 2Health News:Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream(TM)20 Portable Bedside Monitors into the Masimo Patient SafetyNet(TM) System 3Health News:Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream(TM)20 Portable Bedside Monitors into the Masimo Patient SafetyNet(TM) System 4Health News:Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream(TM)20 Portable Bedside Monitors into the Masimo Patient SafetyNet(TM) System 5Health News:Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream(TM)20 Portable Bedside Monitors into the Masimo Patient SafetyNet(TM) System 6Health News:Jeff Korte Named as SIU Director, Litigation Solutions, LLC 2
Delicate Desmarres lid retractors, round serrated handle, very thin blades, polished finish, size 1....
2.0 mm cup , straight shaft, Flat handle, length 125.0 mm....
Size 4 - 2.25 mm...
The Storz Protege is an anterior segment unit only....
Medicine Products: